Patents by Inventor Jack R. Barber
Jack R. Barber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090233917Abstract: The present invention provides methods of treating stroke comprising administering an effective amount of one or more of certain hydroxylamine derivatives to a subject in need thereof. The invention also provides pharmaceutical compositions comprising a certain hydroxylamine derivative or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. In certain compositions, the additional therapeutic agent is a second hydroxylamine derivative or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 6, 2009Publication date: September 17, 2009Inventor: Jack R. Barber
-
Publication number: 20090227572Abstract: The present invention provides methods of enhancing healing of wound associated with diabetes, comprising administering an effective amount of one or more of certain hydroxylamine derivatives to a subject in need thereof. In another aspect, the instant invention provides methods of treating or preventing peripheral nervous system neuropathies. Peripheral nervous system neuropathies may but need not be diabetic neuropathies, and may but need not be associated with a diabetic wound. The invention also provides pharmaceutical compositions comprising a certain hydroxylamine derivative or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. In certain compositions and methods, the additional therapeutic agent is a second hydroxylamine derivative or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 17, 2009Publication date: September 10, 2009Applicant: Cytrx CorporationInventors: Jack R. Barber, Shi Chung Ng
-
Patent number: 7070994Abstract: The invention described herein allows the production of recombinant retroviruses (retroviral vector particles) from producer cells which are safer and of higher titer than normal. In addition, methods are provided for making helper cells which, when a recombinant retrovirus genome is introduced to make a producer line, produce particles that are targeted toward particular cell types. Methods are also provided for making recombinant retrovirus systems adapted to infect a particular cell type, such as a tumor, by binding the retrovirus or recombinant retrovirus in the particular cell type. Methods are also provided for producing recombinant retroviruses which integrate in a specific small number of places in the host genome, and for producing recombinant retroviruses from transgenic animals.Type: GrantFiled: July 24, 2002Date of Patent: July 4, 2006Assignee: Oxford Biomedica (UK) Ltd.Inventors: Jack R. Barber, Douglas J. Jolly, James G. Respess, Stephen M. W. Chang
-
Patent number: 6808876Abstract: A method of identifying a compound that modulates the activity of a cellular regulator is provided. The method consists of contacting a sample containing a cellular regulator and a nucleic acid element acted on by the cellular regulator with a test compound under conditions that allow replication or expression of the nucleic acid element or a gene or mRNA operatively linked to the nucleic acid element or gene, and an increase or decrease in the amount of replication or expression in the presence of the test compound compared to the absence of the test compound indicates that the compound has cellular regulator modulatory activity. A method of treating a HCV infection is also provided.Type: GrantFiled: May 2, 2000Date of Patent: October 26, 2004Assignee: Immusol, Inc.Inventors: Martin Kruger, Peter J. Welch, Jack R. Barber
-
Patent number: 6787646Abstract: The invention provides substantially pure tumor suppressor nucleic acid molecules and tumor suppressor polypeptides. The invention also provides hairpin ribozymes and antibodies selective for these tumor suppressor molecules. Also provided are methods of detecting a neoplastic cell in a sample using detectable agents specific for the tumor suppressor nucleic acids and polypeptides.Type: GrantFiled: November 12, 1999Date of Patent: September 7, 2004Assignee: Immusol, Inc.Inventors: Peter J. Welch, Jack R. Barber
-
Publication number: 20040096818Abstract: The present invention provides a hairpin ribozyme library having a randomized recognition sequence, packaged in a vector and operably linked to a promoter suitable for high level expression in a wide variety of cells. The invention comprises using the library in a variety of selection protocols for identifying, isolating and characterizing known or unknown target RNAs, to reveal the phenotypic effects of such cleavage, and to identify the gene products that produce those phenotypic effects.Type: ApplicationFiled: July 2, 2003Publication date: May 20, 2004Applicant: Immusol, IncorporatedInventors: Jack R. Barber, Peter Welch, Soonpin Yei, Richard Tritz
-
Patent number: 6605429Abstract: The present invention provides a hairpin ribozyme library having a randomized recognition sequence, packaged in a vector and operably linked to a promoter suitable for high level expression in a wide variety of cells. The invention comprises using the library in a variety of selection protocols for identifying, isolating and characterizing known or unknown target RNAs, to reveal the phenotypic effects of such cleavage, and to identify the gene products that produce those phenotypic effects.Type: GrantFiled: July 23, 1999Date of Patent: August 12, 2003Assignee: Immusol, IncorporatedInventors: Jack R. Barber, Peter Welch, Soonpin Yei, Richard Tritz
-
Patent number: 6569679Abstract: The present invention provides recombinant viral vectors carrying a vector construct which directs the expression of a gene product (e.g., HSVTK) that activates a compound with little or no cytotoxicity into a toxic product. Also provided are methods of destroying or inhibiting pathogenic agents in a warm blooded animal, comprising the step of administering to the animal a viral vector such as that described above, in order to inhibit or destroy the pathogenic agent.Type: GrantFiled: June 6, 1995Date of Patent: May 27, 2003Assignee: Chiron CorporationInventors: Jack R. Barber, Harry E. Gruber, Douglas J. Jolly
-
Publication number: 20030091546Abstract: Tissue cells of an animal transformed with a multivalent recombinant vector construct are provided. The vector construct expresses a therapeutic protein and either (a) a second protein or active portion thereof capable of inhibiting MHC antigen presentation; (b) an antisense message capable of inhibiting MHC antigen presentation; or (c) a ribozyme capable of inhibiting MHC antigen presentation. Pharmaceutical compositions comprising such multivalent constructs are also provided. The transformed tissue cells are particularly useful within methods for suppressing an immune response.Type: ApplicationFiled: June 26, 2002Publication date: May 15, 2003Inventors: Jack R. Barber, John F. Warner, Michael J. Irwin, Thomas W. Dubensky, Carlos E. Ibanez, Douglas J. Jolly
-
Publication number: 20030051259Abstract: The invention described herein allows the production of recombinant retroviruses (retroviral vector particles) from producer cells which are safer and of higher titre than normal. In addition, methods are provided for making helper cells which, when a recombinant retrovirus genome is introduced to make a producer line, produce particles that are targeted toward particular cell types. Methods are also provided for making recombinant retrovirus systems adapted to infect a particular cell type, such as a tumor, by binding the retrovirus or recombinant retrovirus in the particular cell type. Methods are also provided for producing recombinant retroviruses which integrate in a specific small number of places in the host genome, and for producing recombinant retroviruses from transgenic animals.Type: ApplicationFiled: July 8, 2002Publication date: March 13, 2003Inventors: Jack R. Barber, Douglas J. Jolly, James G. Respess, Stephen M.W. Chang
-
Patent number: 6531307Abstract: The present invention provides recombinant viral vectors carrying a vector construct which directs the expression of a gene product (eg. HSVTK) that activates a compound with little or no cytotoxicity into a toxic product. Also provided are methods of destroying or inhibiting pathogenic agents in a warm blooded animal, comprising the step of administering to the animal a viral vector such as that described above, in order to inhibit or destroy the pathogenic agent.Type: GrantFiled: May 31, 1995Date of Patent: March 11, 2003Assignee: Chiron CorporationInventors: Jack R. Barber, Harry E. Gruber, Douglas J. Jolly
-
Publication number: 20030003567Abstract: The invention described herein allows the production of recombinant retroviruses (retroviral vector particles) from producer cells which are safer and of higher titer than normal. In addition, methods are provided for making helper cells which, when a recombinant retrovirus genome is introduced to make a producer line, produce particles that are targeted toward particular cell types. Methods are also provided for making recombinant retrovirus systems adapted to infect a particular cell type, such as a tumor, by binding the retrovirus or recombinant retrovirus in the particular cell type. Methods are also provided for producing recombinant retroviruses which integrate in a specific small number of places in the host genome, and for producing recombinant retroviruses from transgenic animals.Type: ApplicationFiled: July 24, 2002Publication date: January 2, 2003Inventors: Jack R. Barber, Douglas J. Jolly, James G. Respess, Stephen M.W. Chang
-
Patent number: 6458567Abstract: This invention provides ribozymes useful to treat or prevent Hepatitis C Virus (“HCV”) infection or disease in an organism or subject, as well as methods of treating an HCV infection or disease. Reagents such as vectors, host cells, DNA molecules coding for these ribozymes usefull in methods of treatment and prevention of HCV infection or disease are also provided.Type: GrantFiled: November 1, 1999Date of Patent: October 1, 2002Assignee: Immusol, Inc.Inventors: Jack R. Barber, Peter J. Welch, Richard Tritz, SoonPin Yei, Mang Yu
-
Patent number: 6410326Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.Type: GrantFiled: June 7, 1995Date of Patent: June 25, 2002Assignee: Chiron CorporationInventors: Harry E. Gruber, Douglas J. Jolly, James G. Respess, Paul K. Laikind, Jack R. Barber, Daniel C. St. Louis, Sunil D. Chada, Stephen M. W. Chang, John F. Warner
-
Patent number: 6310045Abstract: The present invention provides methods for inhibiting the growth of selected tumors utilizing recombinant viral vectors. Briefly, within one aspect of the present invention, a method for inhibiting the growth of a selected tumor is provided comprising the step of directly administering to a warm-blooded animal a vector construct which directs the expression of at least one anti-tumor agent, such that the growth of said tumor is inhibited. Representative examples of anti-tumor agents include immune activators and tumor proliferation inhibitors.Type: GrantFiled: June 6, 1995Date of Patent: October 30, 2001Assignee: Chiron CorporationInventors: Jack R. Barber, Douglas J. Jolly, James G. Respess
-
Patent number: 6241982Abstract: The present invention provides recombinant viral vectors carrying a vector construct which directs the expression of a gene product (e.g., HSVTK) that activates a compound with little or no cytotoxicity into a toxic product. Also provided are methods of destroying or inhibiting pathogenic agents in a warm blooded animal, comprising the step of administering to the animal a viral vector such as that described above, in order to inhibit or destroy the pathogenic agent.Type: GrantFiled: June 6, 1995Date of Patent: June 5, 2001Assignee: Chiron CorporationInventors: Jack R. Barber, Harry E. Gruber, Douglas J. Jolly
-
Patent number: 6043077Abstract: This invention provides ribozymes useful to treat or prevent Hepatitis C Virus ("HCV") infection or disease in an organism or subject, as well as methods of treating an HCV infection or disease. Reagents such as vectors, host cells, DNA molecules coding for these ribozymes useful in methods of treatment and prevention of HCV infection or disease are also provided.Type: GrantFiled: October 20, 1997Date of Patent: March 28, 2000Assignee: Immusol Inc.Inventors: Jack R. Barber, Peter J. Welch, Richard Tritz, SoonPin Yei, Mang Yu
-
Patent number: 5997859Abstract: The present invention provides recombinant viral vectors carrying a vector construct which directs the expression of a gene product (e.g., HSVTK) that activates a compound with little or no cytotoxicity into a toxic product. Also provided are methods of destroying or inhibiting pathogenic agents in a warm blooded animal, comprising the step of administering to the animal a viral vector such as that described above, in order to inhibit or destroy the pathogenic agent.Type: GrantFiled: June 6, 1995Date of Patent: December 7, 1999Assignee: Chiron CorporationInventors: Jack R. Barber, Harry E. Gruber, Douglas J. Jolly
-
Patent number: 5856185Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.Type: GrantFiled: June 7, 1995Date of Patent: January 5, 1999Assignee: Chiron CorporationInventors: Harry E. Gruber, Douglas J. Jolly, James G. Respess, Paul K. Laikind, Jack R. Barber, Daniel C. St. Louis, Sunil D. Chada, Stephen M. W. Chang, John F. Warner
-
Patent number: 5817491Abstract: An enveloped vector particle contains gag and pol proteins from a retrovirus, a nucleic acid sequence and an envelope that includes VSV G envelope glycoprotein. The vector particle can be used to introduce nucleic acids into cells.Type: GrantFiled: December 22, 1994Date of Patent: October 6, 1998Assignees: The Regents of the University of California, Chiron Viagene, Inc.Inventors: Jiing-Kuan Yee, Nobuhiko Emi, Theodore Friedmann, Douglas J. Jolly, Jack R. Barber